Anaptysbio (ANAB) EBITDA Margin (2016 - 2026)
Anaptysbio (ANAB) reported EBITDA Margin of -135.03% for Q1 2026, down 36.39 percentage points from -98.64% a year earlier and down 196.95 percentage points from the prior quarter.
Powered by 
Analysis
Anaptysbio (ANAB) EBITDA Margin (2016 - 2026) Analysis & Trends
Over the twelve months ended Mar 31, 2026, Anaptysbio's EBITDA Margin came in at 17.79%, up 106.91 percentage points year-over-year; for FY2025, it came in at 20.65%, up 145.92 percentage points from FY2024.
- EBITDA Margin has increased for three consecutive years, with a five-year change of +51.75 percentage points (FY2020 to FY2025).
- By year, EBITDA Margin came in at -125.27% in FY2024 (+829.21 pp), -954.47% in FY2023 (+158.38 pp), -1112.85% in FY2022 (-1023.90 pp) and -88.95% in FY2021 (-57.86 pp).
- The Q1 2026 figure ranks as the lowest quarterly EBITDA Margin since Q2 2024.
- Year over year, EBITDA Margin gained in seven of the last eight quarters, with an average year-over-year change of +399.40 percentage points.
- The high point for year-over-year EBITDA Margin in five years was Q4 2022 (a gain of 2686.68 percentage points); the low point was Q4 2021 (a drop of 3121.29 percentage points).
- Per Business Quant data, the three quarters before Q1 2026 came in at 61.92% (Q4 2025), 45.66% (Q3 2025) and -116.91% (Q2 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Anaptysbio | 1.47 Bn | 362.02 Mn | - | -135.03% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -135.03% |
| Dec 31, 2025 | 61.92% |
| Sep 30, 2025 | 45.66% |
| Jun 30, 2025 | -116.91% |
| Mar 31, 2025 | -98.64% |
| Dec 31, 2024 | -22.09% |
| Sep 30, 2024 | -75.33% |
| Jun 30, 2024 | -366.12% |
| Mar 31, 2024 | -585.57% |
| Dec 31, 2023 | -466.07% |
| Sep 30, 2023 | -1,132.43% |
| Jun 30, 2023 | -1,155.49% |
| Mar 31, 2023 | -3,219.43% |
| Dec 31, 2022 | -378.80% |
| Sep 30, 2022 | -2,278.96% |
| Jun 30, 2022 | -2,272.70% |
| Mar 31, 2022 | -3,256.39% |
| Dec 31, 2021 | -3,065.48% |
| Sep 30, 2021 | -31.57% |
| Jun 30, 2021 | -1.24% |
API Access
Anaptysbio EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ANAB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "ANAB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ANAB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();